Practical consensus recommendations regarding the management of HER2 neu positive early breast cancer

Over-expression of HER2 is generally considered to be a negative prognostic feature because it accompanies an increase in breast cancer mortality. However, the development of agents that specifically target HER2 has improved the management of patients with these tumours. This expert group used data...

Descripción completa

Detalles Bibliográficos
Autores principales: Bahl, A., Singh, R., Wadhwa, J., Gupta, S., Ahmed, M., Uppal, P. N., Parikh, Purvish M., Aggarwal, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909284/
https://www.ncbi.nlm.nih.gov/pubmed/29721473
http://dx.doi.org/10.4103/sajc.sajc_111_18
Descripción
Sumario:Over-expression of HER2 is generally considered to be a negative prognostic feature because it accompanies an increase in breast cancer mortality. However, the development of agents that specifically target HER2 has improved the management of patients with these tumours. This expert group used data from published literature, practical experience and opinion of a large group of academic oncologists to arrive at these practical consensus recommendations with regards to the use of these agents and the management of HER2 neu early breast cancer for the benefit of community oncologists.

Ejemplares similares